Luis A. Moreno-Ruiz, División de Excelencia Clínica, Coordinación de Innovación en Salud, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México
Pedro Díaz-García, Hospital General de Zona 20 La Margarita, IMSS, Puebla, Puebla, México
Axel H. Hernández-Pineda, División de Auxiliares de Diagnóstico, Unidad Médica de Alta Especialidad (UMAE), Hospital de Cardiología, Centro Médico Nacional (CMN) Siglo XXI, IMSS, Ciudad de México, México
Nelly Rojas-Jácome, División de Auxiliares de Diagnóstico, Unidad Médica de Alta Especialidad (UMAE), Hospital de Cardiología, Centro Médico Nacional (CMN) Siglo XXI, IMSS, Ciudad de México; División de Cardiología, UMAE Hospital de Cardiología, CMN Siglo XXI, IMSS, Ciudad de México; México
Abraham Majluf-Cruz, Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Instituto Mexicano del Seguro Social, Ciudad de México. México
Luis E. Santos-Martínez, Departamento de Terapia Intensiva Postquirúrgica Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
Background: There is limited information on the inappropriate prescription (underdosing or overdosing) of direct oral anticoagulants (DOAC) that inhibit factor Xa in atrial fibrillation (AF) and their relationship with adverse outcomes. Objective: To describe the frequency of inappropriate DOAC prescription and its association with death, thrombotic, or hemorrhagic events. Materials and methods: A total of 167 adults with non-valvular AF treated with DOAC were included. Demographic and clinical data were collected, with a one-year follow-up. Results: Fourteen percent received an inappropriate dose due to underdosing, showing a higher frequency of the composite outcome of thrombotic events (25% vs 3%), ischemic stroke (13% vs 0.7%), and transient ischemic attack (13% vs 1%) compared with appropriate dosing. Inappropriate prescription was independently associated with the composite thrombotic outcome (RR: 16.7; 95% CI: 2.0-46.8; p < 0.01). No significant differences were observed for hemorrhagic events or mortality. Conclusions: Inappropriate DOAC prescription in non-valvular AF significantly increases the risk of thrombotic events, highlighting the need for accurate dose adjustment.
Keywords: Direct acting oral anticoagulants. Inappropriate prescription. Atrial fibrillation.